The In Vitro Pharmacological Profile of Drugs as a Proxy Indicator of Potential In Vivo Organ Toxicities.

The potential of a drug to cause certain organ toxicities is somehow implicitly contained in its full pharmacological profile, provided the drug reaches and accumulates at the various organs where the different interacting proteins in its profile, both targets and off-targets, are expressed. Under this assumption, a computational approach was implemented to obtain a projected anatomical profile of a drug from its in vitro pharmacological profile linked to protein expression data across 47 organs. It was observed that the anatomical profiles obtained when using only the known primary targets of the drugs reflected roughly the intended organ targets. However, when both known and predicted secondary pharmacology was considered, the projected anatomical profiles of the drugs were able to clearly highlight potential organ off-targets. Accordingly, when applied to sets of drugs known to cause cardiotoxicity and hepatotoxicity, the approach is able to identify heart and liver, respectively, as the organs where the proteins in the pharmacological profile of the corresponding drugs are specifically expressed. When applied to a set of drugs linked to a risk of Torsades de Pointes, heart is again the organ clearly standing out from the rest and a potential protein profile hazard is proposed. The approach can be used as a proxy indicator of potential in vivo organ toxicities.

[1]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[2]  Valérie Zuang,et al.  Alternative (non-animal) methods for chemicals testing: Current status and future prospects - Overview , 2002 .

[3]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[4]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[5]  Kristin M. Fabre,et al.  The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline , 2013, Stem Cell Research & Therapy.

[6]  A. Halaris.  Comorbidity between depression and cardiovascular disease. , 2009, International angiology : a journal of the International Union of Angiology.

[7]  R. Schmieder,et al.  Influences of Norepinephrine Transporter Function on the Distribution of Sympathetic Activity in Humans , 2006, Hypertension.

[8]  D. Healy.  Psychiatric Drugs Explained , 2002 .

[9]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[10]  María Rodríguez Martínez,et al.  Elucidating Compound Mechanism of Action by Network Perturbation Analysis Graphical , 2015 .

[11]  S. Coughlin,et al.  Anatomical Profiling of G Protein-Coupled Receptor Expression , 2008, Cell.

[12]  Daniela Schuster,et al.  Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools , 2014, J. Chem. Inf. Model..

[13]  J. Verducci,et al.  MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes , 2013, Scientific Reports.

[14]  Yvonne Will,et al.  Evaluation of drugs with specific organ toxicities in organ-specific cell lines. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  R. Gabathuler.  Blood-brain barrier transport of drugs for the treatment of brain diseases. , 2009, CNS & neurological disorders drug targets.

[16]  David Vidal,et al.  Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms. , 2015, Chemical research in toxicology.

[17]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Khan,et al.  Database of mRNA gene expression profiles of multiple human organs. , 2005, Genome research.

[19]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[20]  Sean Ekins,et al.  Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.

[21]  P. Hevezi,et al.  Gene expression analyses reveal molecular relationships among 20 regions of the human CNS , 2006, Neurogenetics.

[22]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[23]  C. V. Jongeneel,et al.  eVOC: a controlled vocabulary for unifying gene expression data. , 2003, Genome research.

[24]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[25]  Gowraganahalli Jagadeesh,et al.  Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective , 2015, Nature Reviews Drug Discovery.

[26]  P. Artursson,et al.  A High-Throughput Cell-Based Method to Predict the Unbound Drug Fraction in the Brain , 2014, Journal of medicinal chemistry.

[27]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[28]  Thorsten Dickhaus,et al.  Gene Expression Analyses , 2014 .

[29]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[30]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[31]  Manuel C. Peitsch,et al.  Systems Toxicology: From Basic Research to Risk Assessment , 2014, Chemical research in toxicology.

[32]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[33]  Tudor I. Oprea,et al.  Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome , 2011, Clinical pharmacology and therapeutics.

[34]  Martin Jones,et al.  IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels , 2008, Nucleic Acids Res..

[35]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[36]  Jordi Mestres,et al.  Distant polypharmacology among MLP chemical probes. , 2015, ACS chemical biology.

[37]  Jordi Mestres,et al.  Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.

[38]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[39]  J. Mestres,et al.  On the origins of drug polypharmacology , 2013 .

[40]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[41]  Jean-Pierre Valentin,et al.  Secondary Pharmacodynamic Studies and In vitro Pharmacological Profiling , 2010 .

[42]  D. Stepensky,et al.  Prediction of Drug Disposition on the Basis of its Chemical Structure , 2013, Clinical Pharmacokinetics.

[43]  J. Peters.  Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[44]  Richard D. Smith,et al.  Binding MOAD, a high-quality protein–ligand database , 2007, Nucleic Acids Res..

[45]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[46]  M. Dragunow,et al.  Adult human brain cell culture for neuroscience research. , 2010, The international journal of biochemistry & cell biology.

[47]  Andreas Bender,et al.  From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.

[48]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[49]  Jean-Pierre Valentin,et al.  Secondary Pharmacodynamic Studies andIn Vitro Pharmacological Profiling , 2008 .

[50]  Fan Zhang,et al.  HOMER: a human organ-specific molecular electronic repository , 2011, BMC Bioinformatics.

[51]  M. Dragunow.  The adult human brain in preclinical drug development , 2008, Nature Reviews Drug Discovery.

[52]  T. Klabunde,et al.  GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.

[53]  Bryan L Roth,et al.  Massively parallel screening of the receptorome. , 2008, Combinatorial chemistry & high throughput screening.

[54]  Melvin E. Andersen,et al.  Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[55]  S. Porges,et al.  Vagal tone and the physiological regulation of emotion. , 1994, Monographs of the Society for Research in Child Development.

[56]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[57]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[58]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[59]  J. Gerlach,et al.  Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions , 2001, Biological Psychiatry.

[60]  M. Riddle,et al.  The relevance of prolonged QTc measurement to pediatric psychopharmacology. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[61]  H. Parkinson,et al.  A global map of human gene expression , 2010, Nature Biotechnology.

[62]  David Vidal,et al.  Ligand-based approaches to in silico pharmacology. , 2011, Methods in molecular biology.

[63]  Sally Robinson,et al.  Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas. , 2013, Regulatory toxicology and pharmacology : RTP.

[64]  R. Evans,et al.  Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.